Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 29;13(7):1568. doi: 10.3390/cancers13071568

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Pathways to augmenting CAR-NK in AML. RANK = receptor activator of nuclear factor kappa-Β; TIGIT = T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain; PD-1 = programmed cell death protein 1; iKIR = inhibitory killer immunoglobulin receptor; PD-L1 = programmed death-ligand 1; RANKL = receptor activator of nuclear factor kappa-Β ligand; iMiDs = immunomodulatory drugs; FUT6/7 = alpha-1,3-fucosyltransferases 6 and 7; ATRA = all-trans retinoic acid; PARP1 = Poly (ADP-ribose) polymerase 1; CISH = cytokine-inducible sh2-containing protein; CAR = chimeric antigen receptor.